Divi'S Laboratories Profile
Key Indicators
- Authorised Capital ₹ 60.00 Cr
- Paid Up Capital ₹ 53.00 Cr
- Company Age 34 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 520.00 Cr
- Satisfied Charges ₹ 671.72 Cr
- Revenue Growth -11.31%
- Profit Growth -38.68%
- Ebitda -39.44%
- Net Worth 8.67%
- Total Assets 7.84%
About Divi'S Laboratories
Divi's Laboratories Limited (DLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 12 October 1990 and has a history of 34 years and four months. Its registered office is in Rangareddy, Telangana, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532488 and on the National Stock Exchange(NSE) under DIVISLAB.
The Corporate was formerly known as Divi's Research Centre Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 60.00 Cr and a paid-up capital of Rs 53.00 Cr.
The company currently has active open charges totaling ₹520.00 Cr. The company has closed loans amounting to ₹671.72 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Divi's Laboratories Limited India are Kishore Lingamneni as Cfo, Satchandra Divi as Ceo, and Satish Meka as Company Secretary. Nimmagadda Ramana, Murali Divi, Satchandra Divi, and Seven other members serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
Industry
What products or services does Divi's Laboratories Limited offer?
Divi'S Laboratories Limited offers a wide range of products and services, including Research and Development (R&D) Work, Product Development Research, Laboratory Chemicals, Herbal Powder, Lutein Powder, Ayurvedic,Herbal Products & Medicine, Herbal Capsules, Pharmaceutical Medicine, Lycopene.
Who are the key members and board of directors at Divi'S Laboratories?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murali Divi  | Managing Director | 12-Oct-1990 | Current |
| Kishore Lingamneni | CFO | 24-May-2014 | Current |
| Satchandra Divi | CEO | 04-Jan-2020 | Current |
| Satish Meka | Company Secretary | 10-Aug-2019 | Current |
Board Members (9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajendra Premchand | Director | 08-Jun-2024 | Current |
| Nimmagadda Ramana | Whole-Time Director | 01-Oct-1994 | Current |
| Satchandra Divi | Whole-Time Director | 10-Aug-2001 | Current |
| Motaparti Nilima | Whole-Time Director | 27-Jun-2017 | Current |
| Rameshbabu Nimmagadda | Director | 27-Jun-2017 | Current |
| Ganapaty Seru | Director | 22-Jul-2017 | Current |
Financial Performance of Divi'S Laboratories.
Divi'S Laboratories Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.31% decrease. The company also saw a substantial fall in profitability, with a 38.68% decrease in profit. The company's net worth moved up by a moderate rise of 8.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Divi'S Laboratories?
In 2023, Divi'S Laboratories had a promoter holding of 51.94% and a public holding of 48.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
My Home Industries Private LimitedVeerayya Kosaraju is a mutual person
Genome FoundationVeerayya Kosaraju is a mutual person
Divi's Properties Private LimitedMurali Divi, Satchandra Divi and 1 more are mutual person
Ccl Products (India) LimitedVeerayya Kosaraju is a mutual person
Eugia Pharma Specialities LimitedVeerayya Kosaraju is a mutual person
Anant Raj LimitedVeerayya Kosaraju is a mutual person
Charges (Loans)
₹520.00 Cr
₹671.72 Cr
Charges Breakdown by Lending Institutions
- State Bank Of India : 454.50 Cr
- Hdfc Bank Limited : 60.50 Cr
- Industrial Development Bank Of India : 5.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Feb 2019 | Hdfc Bank Limited | ₹60.50 Cr | Open |
| 06 Feb 2000 | Industrial Development Bank Of India | ₹5.00 Cr | Open |
| 14 Dec 1995 | State Bank Of India | ₹454.50 Cr | Open |
| 28 Oct 2006 | The Bank Of Nova Scotia | ₹20.90 Cr | Satisfied |
| 15 Jun 2006 | State Bank Of India - Overseas Branch | ₹50.58 Cr | Satisfied |
How Many Employees Work at Divi'S Laboratories?
Divi'S Laboratories has a workforce of 11560 employees as of Sep 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Divi'S Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Divi'S Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
